Helixmith Co. Ltd Market Cap ($40.39 Million)
Market Cap & Net Worth: Helixmith Co. Ltd (084990)
Helixmith Co. Ltd market cap. Helixmith Co. Ltd (KQ:084990) has a market capitalization of $40.39 Million (₩59.60 Billion) as of November 3, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22496 globally and #1455 in its home market, demonstrating a -4.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Helixmith Co. Ltd's stock price ₩3735.00 by its total outstanding shares 15956300 (15.96 Million). Also see 084990 cash generation efficiency for how efficiently the company converts equity into cash flow.
Helixmith Co. Ltd Market Cap History (2015–2026)
Helixmith Co. Ltd market cap history from 2015 to 2026. Data shows change from $1.03 Billion to $40.39 Million (-22.70% CAGR). Check 084990 share price today for real-time trading data and today's change.
Index Memberships
Helixmith Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$211.91 Billion | 0.02% | #705 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$211.91 Billion | 0.02% | #705 of 1384 |
Weight: Helixmith Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Helixmith Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Helixmith Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Helixmith Co. Ltd (084990) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.03x
Helixmith Co. Ltd's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $599.64 Million | $6.84 Billion | -$714.46 Million | 0.09x | N/A |
| 2017 | $946.09 Million | $3.16 Billion | -$6.50 Billion | 0.30x | N/A |
| 2018 | $1.47 Billion | $3.13 Billion | -$28.73 Billion | 0.47x | N/A |
| 2019 | $684.02 Million | $4.45 Billion | -$107.04 Billion | 0.15x | N/A |
| 2020 | $324.40 Million | $4.30 Billion | -$82.86 Billion | 0.08x | N/A |
| 2021 | $245.46 Million | $2.32 Billion | -$50.94 Billion | 0.11x | N/A |
| 2022 | $114.08 Million | $2.80 Billion | -$43.54 Billion | 0.04x | N/A |
| 2023 | $66.72 Million | $4.20 Billion | -$64.09 Billion | 0.02x | N/A |
| 2024 | $29.20 Million | $4.97 Billion | -$15.47 Billion | 0.01x | N/A |
| 2025 | $67.26 Million | $2.60 Billion | -$434.92 Million | 0.03x | N/A |
Competitor Companies of 084990 by Market Capitalization
Companies near Helixmith Co. Ltd in the global market cap rankings as of November 3, 2026. Also see Helixmith Co. Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Helixmith Co. Ltd by market ranking:
- MSC Co. Ltd (KQ:009780): Ranked #19639 globally with a market cap of $84.80 Million USD ( ₩125.14 Billion KRW).
- FarmStory Co. Ltd (KQ:027710): Ranked #20617 globally with a market cap of $66.38 Million USD ( ₩97.95 Billion KRW).
- KC Feed Co. Ltd (KQ:025880): Ranked #24402 globally with a market cap of $23.82 Million USD ( ₩35.15 Billion KRW).
- Beeio Honey Ltd (TA:WTS): Ranked #25669 globally with a market cap of $15.84 Million USD ( ILA5.91 Billion ILA).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #19639 | MSC Co. Ltd | KQ:009780 | $84.80 Million | ₩7110.00 |
| #20617 | FarmStory Co. Ltd | KQ:027710 | $66.38 Million | ₩1119.00 |
| #24402 | KC Feed Co. Ltd | KQ:025880 | $23.82 Million | ₩2150.00 |
| #25669 | Beeio Honey Ltd | TA:WTS | $15.84 Million | ILA190.00 |
Market Capitalization of Helixmith Co. Ltd (2015–2026)
Market capitalization of Helixmith Co. Ltd from 2015 to today. Between 2015 and today, Helixmith Co. Ltd's market cap moved from $1.03 Billion to $ 40.39 Million, with a yearly change of -22.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩40.39 Million | -39.95% |
| 2025 | ₩67.26 Million | +130.37% |
| 2024 | ₩29.20 Million | -56.24% |
| 2023 | ₩66.72 Million | -41.52% |
| 2022 | ₩114.08 Million | -53.52% |
| 2021 | ₩245.46 Million | -24.33% |
| 2020 | ₩324.40 Million | -52.57% |
| 2019 | ₩684.02 Million | -53.52% |
| 2018 | ₩1.47 Billion | +55.54% |
| 2017 | ₩946.09 Million | +57.78% |
| 2016 | ₩599.64 Million | -41.85% |
| 2015 | ₩1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Helixmith Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.39 Million USD |
| MoneyControl | $40.39 Million USD |
| MarketWatch | $40.39 Million USD |
| marketcap.company | $40.39 Million USD |
| Reuters | $40.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Helixmith Co. Ltd
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological… Read more